

Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Amicus Therapeutics's Net Promoter Score (NPS) is a -100 with 0% Promoters, 0% Passives, and 100% Detractors. Net Promoter Score tracks whether Amicus Therapeutics's customers would recommend using the product based on a scale of -100 to 100.
| 0% | Promoters |
|---|---|
| 0% | Passives |
| 100% | Detractors |
| Summary | Date | Score |
|---|---|---|
Jul 2021 -100 | Jul 2021 | -100 |
Net Promoter Score (NPS) is a management tool that can be used to gauge the satisfaction of a firm's customer relationships. NPS has been widely adopted as a key metric often linked to the revenue potential of a company’s product or service. The metric is based on customer responses to the question: "On a scale of 0 to 10, how likely are you to recommend the product to a friend?"
Those who respond with a score of 9 to 10 are known as Promoters, and are widely associated with behaviors that create value, including actively encouraging others to use the product or service. Those who respond with a score of 7 or 8 are categorized as Passives, and they are believed to be less likely to exhibit the value-creation traits of Promoters having a largely neutral effect on other consumers. Detractors are those who fall in the score range of 0 to 6 and represent dissatisfied customers of the product sometimes actively recommending against using the product.
Amicus Therapeutics has a 3.7/5 stars for its overall company culture rated by their employees

Amicus Therapeutics scored a -100 for Net Promoter Score and a 34 for Employee Net Promoter Score. NPS gauges how likely a customer of Amicus Therapeutics would recommend the brand to a friend. ENPS measures how likely Amicus Therapeutics employees would recommend working at Amicus Therapeutics to a friend.
| 0% | Promoters |
|---|---|
| 0% | Passive |
| 100% | Detractors |
| 67% | Promoters |
|---|---|
| 0% | Passive |
| 33% | Detractors |